Related Experiment Videos
Protein expression plasmids produced rapidly: streamlining cloning protocols and robotic handling.
Maria Kornienko1, Allison Montalvo, Brian E Carpenter
1Department of Structural Biology, Merck Research Laboratories, West Point, PA 19486, USA. maria.kornienko@merck.com
Assay and Drug Development Technologies
|January 28, 2006
Summary
High-throughput cloning enables parallel production of 192 expression plasmids for drug discovery, achieving over 95% success. This automated process significantly reduces hands-on time for protein crystallization and screening.
Area of Science:
- Biotechnology
- Molecular Biology
- Drug Discovery
Background:
- Preclinical drug discovery requires parallel protein production for screening and crystallization.
- Increasingly parallel processes necessitate automated, high-throughput cloning solutions.
- Low failure rates are critical for efficient DNA construction in large-scale projects.
Purpose of the Study:
- To develop and present automated high-throughput cloning solutions.
- To achieve parallel production of a large number of diverse expression plasmids.
- To optimize DNA construction rates for drug discovery workflows.
Main Methods:
- Utilized Beckman Coulter Biomek FX liquid handler for automated manipulations.
- Employed Gateway cloning technology for efficient DNA recombination.
- Developed custom computer programs for parallel sample information processing, primer design, and sequence assembly.
Main Results:
- Successfully produced 192 different expression plasmids.
- Achieved a success rate greater than 95% for targeted open reading frames.
- Reduced completion time to approximately 11 working days for a single operator.
Conclusions:
- Automated high-throughput cloning significantly enhances efficiency in preclinical drug discovery.
- The presented system enables rapid parallel production of expression plasmids.
- This approach is exemplified by the successful crystallization of Rho-kinase 2 (ROCK2).